Santhera Pharmaceuticals Holding AG

Santhera Pharmaceuticals Holding AG is a specialty pharmaceutical company based in Pratteln, Switzerland, dedicated to the development and commercialization of innovative medicines for rare neuromuscular and pulmonary diseases with high unmet medical needs. The company's mission is to provide treatment options for patients affected by severe conditions, particularly in the area of neuromuscular disorders.

Santhera's key product is AGAMREE® (vamorolone), a first-in-class dissociative steroid approved for the treatment of Duchenne muscular dystrophy (DMD) in the U.S., the EU, and the UK. The company also has a clinical pipeline that includes Lonodelestat (POL6014) for cystic fibrosis and other neutrophilic lung diseases, and an exploratory gene therapy approach for congenital muscular dystrophies.

In its full-year 2025 results, Santhera reported a near-doubling of revenues to CHF 77.2 million, driven by strong AGAMREE sales in Europe and contributions from its partners in the US and China. AGAMREE has seen rapid adoption in core European markets like Germany, Austria, and the UK. The company anticipates reaching cash flow breakeven in Q3 2026 without requiring additional funding. Dario Eklund serves as the CEO.